<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Massachusetts-based cell-centric AI drug discovery company Cellarity and Novo Nordisk have entered a research collaboration to develop new treatment approaches for cardiometabolic diseases. This collaboration is part of an existing partnership between Novo Nordisk and Flagship Pioneering to utilize Flagship's bio platform companies.
      </p>
    </li>
    <li>
      <p>
        As part of the agreement, Novo Nordisk will reimburse the R&amp;D cost and Cellarity will receive up to USD 532 million in upfront payments, development and commercial milestones, as well as tiered royalties on annual net sales.
      </p>
    </li>
    <li>
      <p>
        The partnership will leverage Cellarity&rsquo;s technology to identify novel therapeutics against metabolic dysfunction-associated steatohepatitis (MASH) disease progression and develop a small-molecule therapy.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167006">
      Press release
    </a>
  </p>
  <p>
    <a href="https://pf-media.co.uk/news/novo-nordisk-enters-into-research-collaborations-with-omega-therapeutics-and-cellarity/">
      PF Media 
    </a>
  </p>
  <p>
  </p>
</div>


AI Drug Discovery

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 <p>AI drug discovery firm Cellarity and Novo Nordisk are collaborating to develop treatment methods for cardiometabolic diseases, as part of a partnership between Novo Nordisk and Flagship Pioneering. Novo Nordisk will cover the R&amp;D expenses and Cellarity will receive up to USD 532 million in upfront payments, development and commercial milestones, in addition to tiered royalties on annual net sales.</p>
 <p>The collaboration will utilise Cellarity’s tech to discover new therapeutics against metabolic dysfunction-associated steatohepatitis disease progression and develop a small-molecule therapy.</p>
</div>

All Updates

Cellarity and Novo Nordisk collaborate for cardiometabolic disease treatments

Cellarity raises USD 121 million in a Series C Funding Round